Ophthalmology Search
Ophthalmology Ophthalmology
blepharitis
BLEPHARITIS
Blepharitis is an inflammation process affecting the eyelid margins, eyelash follicles or openings of the anteriorly-placed accessory lacrimal glands and the posteriorly-placed Meibomian glands that causes ocular irritation and redness acutely but usually chronically.
It may have periods of exacerbations and remissions.
It usually occurs in middle-aged adults but can also start in childhood.
Can affect vision by disrupting the surface of the cornea and the bulbar conjunctiva; may influence tear film composition.

Blepharitis References

  1. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  2. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern Guidelines. Blepharitis - limited revision. AAO. www.aao.org/ppp. 2011.
  3. American Academy of Ophthalmology Cornea/External Disease Panel. Preferred Practice Pattern® Guidelines. Blepharitis. AAO. http://www.aao.org/preferred-practice-pattern/blepharitis-ppp.
  4. American Optometric Association Original Consensus Panel. Optometric clinical practice guideline. Care of the patient with ocular surface disorders. American Optometric Association. St. Louis, MO; 2011.
  5. Fort G, Mikolich D. Blepharitis. Ferri: Ferri’s clinical advisor. 1st: Mosby, an imprint of Elsevier; 2012.
  6. Ganatra J, Goldstein M. Blepharitis. In: Yanoff M, Duker JS, et al. Ophthalmology. 3rd ed: Mosby, an imprint of Elsevier; 2009.
  7. Shtein RM. Blepharitis. UpToDate. http://uptodate.com. 2015 Mar.
Editor's Recommendations
Most Read Articles
Early-phase trial evidence for RRMM treatment highly heterogenous
2 days ago
While early-phase clinical trials may demonstrate substantial levels of overall response rates in patients with relapsed/refractory multiple myeloma (RRMM), high heterogeneity of evidence prevents the accurate assessment of clinical benefit before patient participation, reports a recent meta-analysis.
AstraZeneca-Oxford COVID-19 vaccine 79 percent effective in US trial
Elvira Manzano, 28 Mar 2021
The COVID-19 vaccine AZD1222 by AstraZeneca and the University of Oxford was 79 percent effective overall in preventing symptomatic infections – higher than observed in previous clinical trials of the vaccine – at the interim analysis of a US phase III trial.
Endometrial thickness does not dictate embryo transfer outcome
2 days ago
The chances of a live birth following either fresh or frozen-thawed embryo transfer cycles cannot be predicted by endometrial thickness alone, according to a study.
A non-pharmaceutical approach to managing migraine and headache
01 Apr 2021
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.